Neurosense Therapeutics Ltd (NRSN) - Total Liabilities
Based on the latest financial reports, Neurosense Therapeutics Ltd (NRSN) has total liabilities worth $2.59 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check NRSN financial resilience to evaluate the company's liquid asset resilience ratio.
Neurosense Therapeutics Ltd - Total Liabilities Trend (2019–2025)
This chart illustrates how Neurosense Therapeutics Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see NRSN asset base.
Neurosense Therapeutics Ltd Competitors by Total Liabilities
The table below lists competitors of Neurosense Therapeutics Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Pharma Equity Group A/S Cl A
CO:PEG
|
Denmark | Dkr13.43 Million |
|
Connection Technology Systems
TWO:3672
|
Taiwan | NT$245.01 Million |
|
Playtech Plc
LSE:PTEC
|
UK | GBX765.50 Million |
|
Taiwan Thick-Film Ind
TWO:6246
|
Taiwan | NT$887.83 Million |
|
OXE Marine AB
ST:OXE
|
Sweden | Skr163.98 Million |
|
Raptis Group Ltd
AU:RPG
|
Australia | AU$62.52K |
|
Genomtec S.A.
WAR:GMT
|
Poland | zł6.01 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down Neurosense Therapeutics Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Neurosense Therapeutics Ltd net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.31 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.66 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.52 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Neurosense Therapeutics Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Neurosense Therapeutics Ltd (2019–2025)
The table below shows the annual total liabilities of Neurosense Therapeutics Ltd from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $2.59 Million | +29.92% |
| 2024-12-31 | $1.99 Million | -59.71% |
| 2023-12-31 | $4.94 Million | +136.44% |
| 2022-12-31 | $2.09 Million | -13.77% |
| 2021-12-31 | $2.42 Million | +1920.83% |
| 2020-12-31 | $120.00K | +224.32% |
| 2019-12-31 | $37.00K | -- |
About Neurosense Therapeutics Ltd
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for t… Read more